The Singapore Health Sciences Authority (HSA) published a Safety Alert for Finasteride on 30-August-2022.
Suicidal ideation is a known adverse event (AE) observed with the use of finasteride post-market and is listed in the local package inserts of finasteride-containing products.
A recent pharmacovigilance study by Nguyen et al. suggested that younger patients with alopecia (baldness) may be more vulnerable to the risk of suicidality, although this association might be biased by stimulated reporting.
To date, HSA has received one report of a 19-year-old male who developed severe mental depression with suicidal tendencies after one month’s use of finasteride 1mg. The patient recovered fully several weeks after stopping the medication.
The local package inserts of finasteride-containing products currently list depression and suicidal ideation as psychiatric AEs observed post-market.